Nicole J. Kim, Daniel Holguin, Dylan Bush, Mandana Khalili – 11 July 2019 – The opioid epidemic has recently increased the rates of hepatitis C virus (HCV) infection among young women. We therefore aimed to characterize the cascade of HCV care in a cohort of underserved women of reproductive age. Medical records of 19,121 women between the ages of 15 and 44 years, receiving primary care in the San Francisco safety‐net health care system, were reviewed.

Jiahui Li, Huimin Liu, Amy S. Mauer, Fabrice Lucien, Abagail Raiter, Harikrishna Bandla, Taofic Mounajjed, Ziying Yin, Kevin J. Glaser, Meng Yin, Harmeet Malhi – 10 July 2019 – Circulating extracellular vesicles (EVs) are a novel and emerging biomarker for nonalcoholic steatohepatitis (NASH). It has been demonstrated that total circulating EVs and hepatocyte‐derived EVs are elevated in male mice with diet‐induced NASH. How hepatocyte‐derived EVs change over time and other cellular sources of EVs in NASH have not been determined.

Kelly L. Hayward, Patricia C. Valery, W. Neil Cottrell, Katharine M. Irvine, Jennifer H. Martin, Elizabeth E. Powell – 10 July 2019

Indira Bhavsar, Jennifer Wang, Sean M. Burke, Kimberly Dowdell, R. Ann Hays, Nicolas M. Intagliata – 10 July 2019

This webinar will discuss the management of renal insufficiency in patients with cirrhosis, in both the inpatient and outpatient settings. Topics to be discussed include workup of the patient with acute kidney injury in the outpatient setting, management of diuretics and evaluation using novel biomarkers.

Mary E. Rinella, Frank Tacke, Arun J. Sanyal, Quentin M. Anstee, on behalf of the participants of the AASLD/EASL Workshop – 9 July 2019 – Nonalcoholic fatty liver disease (NAFLD) is a global public health concern. Its natural history, the development of nonalcoholic steatohepatitis (NASH) and fibrosis, is highly variable, prone to endogenous (e.g., genetics, microbiota) and exogenous (e.g., nutrition, alcohol, physical activity) disease modifiers, and can fluctuate over time. The complexity of its pathophysiology is reflected by the multitude of pharmacological targets in development.

Marie Sinclair, Brooke Chapman, Rudolf Hoermann, Peter W. Angus, Adam Testro, Thomas Scodellaro, Paul J. Gow – 8 July 2019 – Sarcopenia is associated with mortality in cirrhosis, but there is no gold standard for its diagnosis. The comparative utility of different diagnostic methods is unknown. This single‐center observational cohort study followed 145 men referred for liver transplant evaluation between 2005 and 2012.

Kyle E. Korolowizc, Bin Li, Xu Huang, Changsuek Yon, Evelyn Rodrigo, Manny Corpuz, David M. Plouffe, Bhaskar V. Kallakury, Manasa Suresh, Tom Y.‐H. Wu, Andrew T. Miller, Stephan Menne – 8 July 2019 – Current therapeutics for chronic infection with hepatitis B virus (HBV) rarely induce functional cure due to the immunotolerant status of patients. Small molecule agonists targeting toll‐like receptor 7 (TLR7) have been shown to elicit a functional cure in animal models of HBV but sometimes with poor tolerability due to immune‐related toxicities.

Rianne A. Weersink, Joost P.H. Drenth, Nicole G.M. Hunfeld, Sander D. Borgsteede – 8 July 2019

Yongzhen Liu, Hui Liu, Zhanying Hu, Yang Ding, Xiao‐Ben Pan, Jun Zou, Jingyuan Xi, Guangxin Yu, Hongxin Huang, Meng‐Ting Luo, Fang Guo, Shuang Liu, Qiuju Sheng, Jidong Jia, Yong‐Tang Zheng, Jie Wang, Xiangmei Chen, Ju‐Tao Guo, Lai Wei, Fengmin Lu – 6 July 2019 – Nucleos(t)ide analogues (NAs) have been widely used for the treatment of chronic hepatitis B (CHB). Because viral DNA polymerase lacks proofreading function (3′ exonuclease activity), theoretically, the incorporated NAs would irreversibly terminate viral DNA synthesis.